Sinovac Biotech Ltd. (SVA)

Overview

Sinovac Biotech Ltd. is a pioneering biopharmaceutical company with a dedicated focus on the research, development, manufacture, and commercialization of vaccines to combat human infectious diseases. Operating primarily within the People's Republic of China, Sinovac has established a strong presence in the vaccine industry through its innovative approaches and significant contributions towards public health. Since its inception in 1993, the company has been headquartered in Beijing, demonstrating its commitment to addressing the vaccination needs of not only the Chinese population but also aiming to impact global health standards positively.

Products and Services

Healive - An inactivated hepatitis A vaccine, designed to provide immunity against the hepatitis A virus.

Bilive - A combined inactivated vaccine for hepatitis A and B, offering protection against both hepatitis A and B viruses.

Anflu - A split viron influenza vaccine aimed at providing protection against seasonal influenza.

Panflu - A vaccine developed against the H5N1 influenza virus, part of the efforts to combat avian influenza.

Panflu.1 - Targeted at controlling the spread of the influenza A H1N1 virus, this vaccine is a response to pandemic influenza strains.

Mumps Vaccine - Designed to prevent mumps, a viral disease affecting the human species, ensuring immunity through vaccination.

Inlive - A vaccine against Enterovirus 71 (EV71), which causes hand, foot, and mouth disease, a significant health concern in children.

Varicella Vaccine - Provides immunity against varicella, a highly contagious disease known to cause chickenpox.

Pneumococcal Polysaccharide Vaccine - Aims to prevent infections caused by Streptococcus pneumoniae, including pneumonia and septicemia.

Quadrivalent Influenza Vaccine - A comprehensive vaccine protecting against two strains of influenza A viruses and two strains of influenza B viruses.

CoronaVac - A COVID-19 vaccine developed to combat the coronavirus pandemic, showcasing Sinovac’s adaptability to emerging infectious diseases.

In addition to these marketed products, Sinovac's pipeline includes significant projects like a sabin inactivated polio vaccine, which has completed phase III clinical trial and a rubella vaccine that promises to broaden the company's infectious disease coverage. Collaboration agreements with prestigious institutions and companies, such as GlaxoSmithKline Biologicals SA, Tianjin CanSino Biotechnology Inc., and Instituto Butantan, underline Sinovac's commitment to advancing vaccine development through partnerships, enhancing its portfolio, and contributing to the global fight against infectious diseases.